RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa
| Status: | Recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/5/2019 |
| Start Date: | December 14, 2015 |
| End Date: | October 31, 2033 |
| Contact: | Clinical Trials Registry Team |
| Email: | IR-CTRegistration@Allergan.com |
| Phone: | 877-277-8566 |
Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)
RST-001 is a gene therapy given as an injection into the eye.
Inclusion criteria:
Participants must meet all of the following criteria.
1. Age >= 18 years
2. Signed and dated written informed consent obtained from the patient.
3. Ability to comply with testing and all protocol tests.
Exclusion criteria:
Any one of the following will exclude patients from being enrolled into the study:
1. Unable or unwilling to meet requirements of the study;
2. Participation in a clinical study (ocular or non-ocular) with an investigational drug,
agent or therapy in the past six months
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
San Francisco, California 94143
Phone: 415-514-4240
Click here to add this to my saved trials